Leisure Acquisition

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company was founded in April 2003 and is headquartered in La Jolla, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW) today announced that the Company will begin trading its common stock under the ticker symbol “ENSC” on The Nasdaq Capital Market and warrants under the ticker symbol “ENSCW” on the OTC Market on July 2, 2021.

Ensysce Biosciences to Begin Trading its Common Stock on The Nasdaq Capital Market on July 2, 2021

SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (OTC: LACQ, LACQW) today announced that, in connection with the closing of its previously announced merger with Leisure Acquisition Corp. (“LACQ”), the combined company, Ensysce Biosciences, Inc., will commence trading its common stock and warrants under the ticker symbols “LACQ” and “LACQW,” respectively, on the OTC Market on July 1, 2021.

Ensysce Biosciences to Commence Trading on the OTC on July 1, 2021

NEW YORK, June 1, 2021 /PRNewswire/ -- Leisure Acquisition Corp. ("LACQ" or the "Company") (Nasdaq: LACQ, LACQU, LACQW), a special purpose acquisition company formed for the purpose of effecting a merger, acquisition or similar business combination, announced today that on June 1, 2021, Nasdaq notified LACQ that trading in the Company's securities on Nasdaq will be suspended effective with the open of the market on Thursday, June 3, 2021 due to the Company's failure to complete an initial business combination by June 1, 2021, which date the notice stated represented the full extent of the Nasdaq Hearing Panel's discretion in this matter. The Company expects that its securities will be immediately eligible to trade on the OTC Markets system on Thursday, June 3, 2021.

Leisure Acquisition Corp. Announces Receipt of and Plan to Appeal Nasdaq Listing Determination

NEW YORK and SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- Ensysce Biosciences Inc. ("Ensysce"), a clinical stage pharmaceutical company developing medicines for severe pain relief to reduce fear of addiction, opioid misuse, abuse and overdose, and Leisure Acquisition Corp. (NASDAQ: LACQ)...

Ensysce Biosciences, Inc. And Leisure Acquisition Corp. Announce Appointment Of Dave Humphrey As Chief Financial Officer

New York, New York--(Newsfile Corp. - February 12, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Leisure Acquisition Corp. ("Leisure Acquisition" or the "Company") (NASDAQ: LACQ) stock prior to February 1, 2021.You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation in

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Leisure Acquisition Corp. with Ensysce Biosciences, Inc.

NEW YORK, Feb. 3, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Leisure Acquisition Corp. ("Leisure" or the "Company") (NASDAQ: LACQ), a special purpose acquisition company, in connection...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Leisure Acquisition Corp.

Hyliion

Nikola

Virgin Galactic

Tuscan Holdings

However, history confirms that many SPAC IPOs don't deliver returns on par with comparable companies that went public the traditional route. Additionally, not all SPACs find a company to partner with, meaning the blank-check firm, if it doesn't accomplish that goal within two years, is vulnerable to liquidation.

5 SPAC IPOs That Could Sooner Go To Zero

Acamar Partners Acquisition Corp

Act II Global Acquisition Corp - Ordinary Shares - Class A

Conyers Park III Acquisition Corp

Diamond Eagle Acquisition Corp - Unit (1 Ordinary share Cls A & 1/3 Wrt)

Haymaker Acquisition Corp 4

Oaktree Acquisition Corp

Repay Holdings Corp

As the markets continue further into bear-market territory, investors might want to consider some of these SPAC IPO stocks.

10 SPAC IPO Stocks to Buy As the Market Enters Bear Territory

News for Leisure Acquisition Stock (LACQ)